Vanguard Group
IBO

Vanguard Group’s Impact BioMedical IBO Stock Holding History

Vanguard Group’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$412K Buy
814,885
+711,980
+692% +$377K ﹤0.01% 3979
2025
Q3 		$68.4K Buy
102,905
+70,468
+217% +$44.4K ﹤0.01% 4262
2025
Q2 		$21K Sell
32,437
-94,009
-74% -$52.7K ﹤0.01% 4244
2025
Q1 		$110K Buy
+126,446
New +$219K ﹤0.01% 4129

Other funds holding IBO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vanguard Group's IBO Position: Q4 2025 in Review

Vanguard Group increased its Impact BioMedical (IBO) stake by 692% in Q4 2025, buying an estimated $377K and bringing the position to 814,885 shares worth $412K. The position accounts for ﹤0.01% of the portfolio, ranked #3979.

Vanguard Group first reported a position in IBO in Q1 2025 and has held it in 4 quarters since. 24 funds tracked by Wall St. Rank hold IBO as of Q4 2025.

  • Vanguard Group held 814,885 shares of Impact BioMedical worth $412K as of Q4 2025.
  • Vanguard Group bought 711,980 Impact BioMedical shares in Q4 2025, an estimated $377K.
  • Impact BioMedical made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3979 holding.
  • Vanguard Group first reported a position in Impact BioMedical in Q1 2025 and has held it in 4 quarters since.
  • 24 funds tracked by Wall St. Rank held Impact BioMedical as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.